[go: up one dir, main page]

ATE248147T1 - Piperidine derivate als inhibitoren der neurotransmitter-wiederaufbaunahme - Google Patents

Piperidine derivate als inhibitoren der neurotransmitter-wiederaufbaunahme

Info

Publication number
ATE248147T1
ATE248147T1 AT98919091T AT98919091T ATE248147T1 AT E248147 T1 ATE248147 T1 AT E248147T1 AT 98919091 T AT98919091 T AT 98919091T AT 98919091 T AT98919091 T AT 98919091T AT E248147 T1 ATE248147 T1 AT E248147T1
Authority
AT
Austria
Prior art keywords
alkynyl
cycloalkyl
alkenyl
alkyl
heteroaryl
Prior art date
Application number
AT98919091T
Other languages
English (en)
Inventor
Peter Moldt
Frank Waetjen
Jorgen Scheel-Krueger
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE248147T1 publication Critical patent/ATE248147T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98919091T 1997-05-14 1998-05-12 Piperidine derivate als inhibitoren der neurotransmitter-wiederaufbaunahme ATE248147T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK55397 1997-05-14
PCT/DK1998/000185 WO1998051668A1 (en) 1997-05-14 1998-05-12 Piperidine derivatives as neurotransmitter re-uptake inhibitors

Publications (1)

Publication Number Publication Date
ATE248147T1 true ATE248147T1 (de) 2003-09-15

Family

ID=8094843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98919091T ATE248147T1 (de) 1997-05-14 1998-05-12 Piperidine derivate als inhibitoren der neurotransmitter-wiederaufbaunahme

Country Status (7)

Country Link
US (1) US6376673B1 (de)
EP (1) EP0981515B1 (de)
JP (1) JP2001525812A (de)
AT (1) ATE248147T1 (de)
AU (1) AU7206398A (de)
DE (1) DE69817557T2 (de)
WO (1) WO1998051668A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303627B1 (en) 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
US7517892B2 (en) 2000-09-11 2009-04-14 Sepracor Inc. Ligands for monoamine receptors and transporters, and methods of use thereof
US20020161002A1 (en) * 2001-01-02 2002-10-31 Mel Epstein Use of catecholamine reuptake inhibitors to enhance memory
EP1560813B1 (de) 2002-11-01 2010-03-17 NeuroSearch A/S Neue piperidinderivate und deren verwendung als monoaminneurotransmitter-wiederaufnahmehemmer
JP4565087B2 (ja) 2002-12-02 2010-10-20 ゼノム リミティッド 新規なχ−コノトキシン・ペプチド（−Ｉ）
EP1578787B1 (de) 2002-12-02 2012-11-14 Xenome Ltd Neue chi-conotoxinpeptide (-ii)
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
JP2009518337A (ja) 2005-12-07 2009-05-07 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ 皮質カテコールアミン作動性神経伝達のモジュレーターとしての二置換フェニルピペリジン
WO2010130672A1 (en) * 2009-05-12 2010-11-18 Glaxo Group Limited Azabicyclo [4.1.0] heptane derivatives and their use as monoamine reuptake inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048165A (en) * 1975-08-11 1977-09-13 Basf Aktiengesellschaft Manufacture of 1-substituted oximino cyclo alkenes-(1)
IT1233446B (it) 1987-12-30 1992-04-01 Roussel Maestretti Spa Derivati della 3 piperidinocarbaldeide ossima, loro procedimento di preparazione e loro applicazione come farmaci
US5021439A (en) * 1988-10-31 1991-06-04 Takeda Chemical Industries, Ltd. Cerebral function ameliorating agents related to Tan-950 A
WO1997009311A1 (de) * 1995-09-07 1997-03-13 F. Hoffmann-La Roche Ag Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz

Also Published As

Publication number Publication date
EP0981515A1 (de) 2000-03-01
DE69817557T2 (de) 2004-06-17
AU7206398A (en) 1998-12-08
JP2001525812A (ja) 2001-12-11
DE69817557D1 (de) 2003-10-02
US6376673B1 (en) 2002-04-23
WO1998051668A1 (en) 1998-11-19
EP0981515B1 (de) 2003-08-27

Similar Documents

Publication Publication Date Title
UA49872C2 (uk) Похідні тропану, спосіб їх одержання, фармацевтична композиція та спосіб лікування
NO980919D0 (no) 8-azabicyklo(3.2.1)okt-2-ene derivater, deres fremstilling og anvendelse
UA49801C2 (uk) Похідні тропан-2-альдоксиму, спосіб їх отримання, фармацевтична композиція, спосіб лікування
DE69623799D1 (de) Kondensierte tropanderivate als neurotransmitter-reuptake-inhibitoren
ATE383338T1 (de) N-(phenyl(piperidin-2-yl)methyl)benzamid-deriva e,verfahren zu deren herstellung und ihre therapeutische verwendung
BR0211201A (pt) Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
DE60031577D1 (de) Hemmer der zelladhäsion
DE69929689D1 (de) Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen
EA200401172A1 (ru) Производные n-[фенил(пиперидин-2-ил)метил]бензамида, способ их получения и их применение в терапии
ATE248147T1 (de) Piperidine derivate als inhibitoren der neurotransmitter-wiederaufbaunahme
ATE374750T1 (de) Serotoninwiederaufnahme-inhibitoren
SE9802360D0 (sv) New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins ((basic)-N-substituted and (basic)-N,N-disubstituted derivatives of 2,6-diamino-thiazolo(4,5-f)indan and 2,7-di-amino-thiazolo(4,5-g)tetralin
HUP0000315A2 (hu) Heterociklusos szubsztituált pirrolidin-amid származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
DE60335960D1 (de) 1,2,4-triazolderivat, verfahren zu dessenherstellung, und dieses enthaltende pharmazeutische zusammensetzung
BR9812928A (pt) Novos derivados de 3-oxo-(2h) -1,2,4-triazina, processo de preparação de compostos quìmicos, e, composição farmacêutica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties